SCHEMBL10106322

SCHEMBL10106322

COc1ccc(C2OCC(C)(C)CO2)cc1C(O)(c1cccc(C)c1)c1cc(C2OCC(C)(C)CO2)ccc1OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.39
NR3C1 P04150 1/20 0.34
ALOX5 P09917 1/20 0.33
PTPN1 P18031 1/20 0.33
PPARG P37231 1/20 0.33
PPARD Q03181 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPT P10636 1/20 0.33
CASP3 P42574 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
SENP6 Q9GZR1 1/20 0.33
MAPK1 P28482 2/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
GAA P10253 3/20 0.32
CHRM2 P08172 1/20 0.32
CHRM3 P20309 1/20 0.32
ACHE P22303 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10106346 0.88 NPC1 (0.39) RAB9ASMN1; SMN2NPC1ALOX5PTPN1
SCHEMBL10106336 0.88 SMN1; SMN2 (0.39) RAB9ASMN1; SMN2NPC1NR3C1ALOX5
SCHEMBL10106383 0.87 SMN1; SMN2 (0.40) RAB9ASMN1; SMN2NPC1NR3C1ALOX5
SCHEMBL7074120 0.83 NPC1 (0.41) RAB9ASMN1; SMN2NPC1NR3C1ALOX5
SCHEMBL10106355 0.83 NPC1 (0.35) RAB9ASMN1; SMN2NPC1MEN1KMT2A
SCHEMBL10330556 0.79 NR3C1 (0.33) RAB9ASMN1; SMN2NPC1NR3C1
SCHEMBL10106418 0.78 NPC1 (0.36) RAB9ASMN1; SMN2NPC1MEN1KMT2A
SCHEMBL10330568 0.78 NPC1 (0.33) RAB9ASMN1; SMN2NPC1MEN1KMT2A
SCHEMBL10106440 0.78 NPC1 (0.35) RAB9ASMN1; SMN2NPC1
SCHEMBL10106337 0.78 EGFR (0.41) RAB9ASMN1; SMN2NPC1MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9321739-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2016-04-26 US disclosed
US-9321739-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2016-04-26 US disclosed
US-8119672-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2012-02-21 US disclosed
US-8119672-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2012-02-21 US disclosed
US-20110305666-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES RYS DAVID J (US) 2011-12-15 US disclosed
US-20110305666-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES RYS DAVID J (US) 2011-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110305666-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES TTPA, HAVCR2, PML RAB9A 2880/4885SMN1; SMN2 1044/4885NPC1 215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.